Generics and Biosimilars Initiative Journal · 2014 · 42 citations · 12 references
PharmacyPharmaceutical PolicyPharmacologyDrug Approval ProcessesPharmaceutical RegulationPharmacovigilanceBiosimilar RegulationDrug ApprovalDrug Safety MonitoringPharmacovigilance CompliancePharmacovigilance RegulationSpontaneous Reporting SystemsGuideline Development For BiosimilarsMarket Access For BiosimilarsPharmacovigilance For BiosimilarsRegulatory Approval PathwaysRegulatory Compliance In PharmacovigilanceRegulatory Frameworks For BiosimilarsRegulatory Safety ReportingSerious Adverse Events
Author byline as per print journal: Valderilio Feijó Azevedo, MD, PhD; Eduardo Mysler, MD; Alexis Aceituno Álvarez, PharmD, PhD; Juana Hughes, MSc; Francisco Javier Flores-Murrieta, PhD, FCP; Eva Maria Ruiz de Castilla, MS, MAA, PhD Abstract: With the emergence of biosimilars as a new class of biotherapeutic agents,
12
Josef S Smolen, Jonathan Kay, Mittie K. Doyle et al. · The Lancet · 2009 · 520 citations
Paul Emery, Roy Fleischmann, Larry W. Moreland et al. · Arthritis & Rheumatism · 2009 · 396 citations · Full text
GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)
English Only · 2009 · 244 citations